Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.71 |
| ▸ | SLC2A9 | Q9NRM0 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19867808 | 0.89 | SLC22A12 (0.76) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL249022 | 0.88 | SLC22A12 (0.78) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL8780267 | 0.88 | SLC22A12 (0.80) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735350 | 0.85 | SLC22A12 (0.82) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL21164758 | 0.84 | SLC22A12 (0.69) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL11915751 | 0.84 | SLC22A12 (0.71) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1299461 | 0.84 | SLC22A12 (0.81) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL842962 | 0.83 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| Lesinurad SCHEMBL29353441 | 0.83 | SLC22A12 (1.00) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4735395 | 0.83 | SLC22A12 (0.70) | SLC22A12CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003681-B2 | 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester | ARDEA BIOSCIENCES, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | ARDEA BIOSCIENCES, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069645-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, ME2 | SLC22A12 1037/4885CYP2C9 927/4885CYP2C19 1109/4885 |
| US-20100081827-A1 | 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AND METHYL ESTER | GRHPR, POLR2H, DECR1 | SLC22A12 1207/4885CYP2C9 840/4885CYP2C19 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.